Viking Therapeutics, Inc. Retained Earnings
Viking Therapeutics, Inc. (VKTX) had Retained Earnings of -$1.13 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-29
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.13B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.01B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$847.55M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$689.88M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$1.13B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | -$1.01B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | -$847.55M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | -$689.88M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | -$599.10M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | -$533.54M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | -$487.91M 10-K · filed 2026-02-11 | |
| 2024-09-30 | -$452.49M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | -$427.55M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | -$405.30M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | -$377.94M 10-K · filed 2025-02-26 | |
| 2023-09-30 | -$353.34M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | -$330.81M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | -$311.58M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | -$292.05M 10-K · filed 2024-02-07 | |
| 2022-09-30 | -$272.49M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | -$256.72M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | -$239.28M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | -$223.18M 10-K · filed 2023-02-10 | |
| 2021-09-30 | -$210.83M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$197.58M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | -$182.20M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | -$168.19M 10-K · filed 2022-02-09 | |
| 2020-09-30 | -$157.24M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | -$147.96M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | -$138.38M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | -$128.70M 10-K · filed 2021-02-17 | |
| 2019-09-30 | -$121.25M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$115.52M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | -$107.84M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | -$102.92M 10-K · filed 2020-02-26 | |
| 2018-09-30 | -$97.68M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$91.08M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$84.41M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | -$80.86M 10-K · filed 2019-03-13 | -$80.85M 10-K · filed 2018-03-07 |
| 2017-09-30 | -$76.77M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$70.67M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$65.50M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$60.28M 10-K · filed 2018-03-07 | |
| 2016-09-30 | -$56.63M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$52.83M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | -$49.13M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$45.55M 10-K · filed 2017-03-21 | |
| 2015-09-30 | -$40.45M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$35.72M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$27.85M 10-Q · filed 2015-06-12 | |
| 2014-12-31 | -$22.14M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |